Bisoprolol Reduce Left Ventricular Hypertrophy in Arg389Arg Hypertensive Patients Receiving Angiotensin-II Receptor Blocker
Keywords:
left ventricular hypertrophy, Arg389Arg, angiotensin-II receptor blocker.Abstract
Left ventricular hypertrophy (LVH) is commonly present in patients with hypertension (HT). Angiotensin-II and chronic stimulation of ?1-adrenergic receptors (?1-AR) contribute to LVH
References
Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens. 2009;27:2458
Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Pressur. 2007;16:135
Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343
Okin PM, Gerdts E, Wachtell K, et al. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens. 2010;28:1534
de Simone G, Gottdiener JS, Chinali M, et al. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart Journal. 2008;29:741
Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of newonset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403
Robert H. Fagard, et al. Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies. In American Heart Association. 2009.
Fagard RH, Celis H, Thijs H, et al. Regression of left ventricular mass by antihypertensive treatment a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084
Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am JMed. 2003;115:41
Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-13.
Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011;5:259
Strader CD, Fong TM, Tota MR, Underwood D, Dixon RA. Structure and function of G-protein-coupled receptors. Annu Rev Biochem. 1994;63:101
Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ. Inhibition of Na(+)
Iemitsu M, Miyauchi T, Maeda S, et al. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol. 2001;281:R2029
Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817
Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059
Hoehe MR, Otterud B, Hsieh WT, et al. Genetic mapping of adrenergic receptor genes in humans. J Mol Med. 1995;73:299
Maqbool A, Hall AS, Ball SG, Balmforth AJ. Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay. Lancet. 1999;353:897.
Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1- adrenergic receptor. J Biol Chem. 1999;274:12670
Moore JD, Mason DA, Green SA, Hsu J, Liggett SB. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145ANG and c1165GNC. Hum Mutat. 1999;14:271.
Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300
Iwai C, Akita H, Kanazawa K, et al. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J. 2003;146:106
Shioji K, Kokubo Y, Mannami T, et al. Association between hypertension and the alpha-adducin, beta1-adrenoreceptor, and G-protein beta3 subunit genes in the Japanese population; the Suita study. Hypertens Res. 2004;27:31
Bengtsson K, Melander O, Orho-Melander M, et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation. 2001;104: 187
Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther. 2003;73:366
Terra SG, Hamilton KK, Pauly DF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005;15:227
Fu Chunyan, Hu ikWang, Shuxia Wang, et al. Association of beta (1)-adrenergic receptor gene polymorphisms with left ventricular hypertrophy in human essential hypertension. Elsevier. 2008; 773-778.
Chobanian AV,et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 complete report. Hypertension. 2003;42:1206
Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998;352(Suppl 1):SI8
Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail. 2000;6:8
Naga Prasad SV, Nienaber J, Rockman HA. Beta-adrenergic axis and heart disease. Trends Genet. 2001;17:S44
Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med. 1998;158: S146
Brodde OE. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203
Buxton IL, Brunton LL. Direct analysis of beta-adrenergic receptor subtypes on intact adult ventricular myocytes of the rat. Circ Res. 1985;56: 126
Friddle CJ, Koga T, Rubin EM, Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2000;97:6745
Weber MA. Interrupting the Rengiotensi System: The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Treatment of Hypertension. Am J Hypertens. 1999 Dec;12:189s-194s.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
